Genmab

	14/7 16:23 af nohope	Fåk - det bliver en dyr dag. Vidste godt det ville køre af sporet da jeg så DOW i går aftes - men alligevel...
	14/7 16:23 af Klarussen	Bliver interessant om bunden i trendkanalen fra midtmarts holder...
	14/7 16:05 af Stroka	Hvem trak bundproppen ud?
	14/7 15:09 af Helge Larsen/PI-redaktør	Velbekommen. :-)
	14/7 15:08 af Mcjean	Har fundet det super, tak Helge for din nye informationside
	14/7 15:08 af Helge Larsen/PI-redaktør	Mcjean...du tjekker bare her. (link) :-)
	14/7 15:06 af Mcjean	Hvornår er det JJ har regnskab, er det 16/7?
	14/7 15:04 af B.Andersen	Det holdt nu ikke mange timer.
	14/7 13:07 af Helge Larsen/PI-redaktør	Flot rebound af Genmab. NOVO og ZEAL bliver stående på perronen. :-)
	14/7 12:12 af Solsen	Abbvie/Genmab har virkelig en hård konkurrent. Håber at data gør det hårde arbejde for dem !
	14/7 12:10 af Solsen	Roche er bare dygtige.
	14/7 11:10 af GeorgeBest	(link)
	14/7 11:10 af GeorgeBest	FDA grants Breakthrough Therapy Designation for Roche’s CD20xCD3 bispecific cancer immunotherapy mosunetuzumab recognising its potential in follicular lymphoma
	14/7 09:59 af E L	could be, it wasn't mentioned in the Genmab investor presentation
	14/7 09:35 af Bulder	Could be this one : (link)
	14/7 09:34 af Bulder	I noticed: "... as well as bladder and renal cell carcinoma previously treated with PD-1/PD-L1 antibodies." A solid study we haven't heard of? Or one of the BMS studies?
	14/7 09:30 af Helge Larsen/PI-redaktør	Super. :-D
	14/7 09:20 af E L	-end-
	14/7 09:20 af E L	future where forthcoming clinical trials use the subcutaneous formulation rather than traditional daraIV. For these reasons, and assuming FDA/EHA approval in the near future, we support the use of dara-SC for both standard of care and investigational use moving forward.
	14/7 09:20 af E L	If ongoing trials show activity in these respective indications the use of the drug will only grow, further stressing health care resources in many areas. Additionally, limiting cancer patients’ time in busy infusion clinics will decrease their potential exposure to current and future pathogens of which they are inherently vulnerable, and at risk for more serious complications if infected. It would be reasonable to envision a
	14/7 09:20 af E L	It is not surprising that daratumumab is currently under evaluation in both other hematologic malignancies (acute lymphoblastic lymphoma, acute myeloid leukemia, non-Hodgkin lymphoma), as well as bladder and renal cell carcinoma previously treated with PD-1/PD-L1 antibodies.
	14/7 09:18 af E L	" One can certainly imagine a case where a patient is given a clinically inferior regimen due to these logistical issues. The development of the subcutaneous formulation of daratumumab reviewed in this paper allows for rapid administration with a significantly diminished risk for daratumumab-related IRRs, potentially allowing expanded access to a powerful anti-myeloma therapy in areas where healthcare resources may be limited"
	14/7 09:18 af E L	"As daratumumab continues to accumulate approvals in more front-line combinations its use is only expected to increase. Unfortunately, the labor intensive, protracted initial infusions and significant risk of IRRs have potentially limited its utility in areas with limited healthcare resources. Indeed, in many areas a patient may need to get their initial 1-2 infusions at a tertiary care facility, with subsequent administrations provided in the community setting."
	14/7 09:15 af Helge Larsen/PI-redaktør	Pharma og biotek under pres som så meget andet her i åbningen.

	14/7 09:14 af E L	"Additionally, the decreased infusion time should translate to improved quality of life, less healthcare resource use, and increased economic benefit in terms of decreased time away from work and increased productivity."
	14/7 09:14 af Helge Larsen/PI-redaktør	Ok. :-)
	14/7 09:02 af Bulder	It's because it's sci-hub. No access from Denmark.
	14/7 09:01 af Helge Larsen/PI-redaktør	The link to the full article do not function for me.
	14/7 08:57 af Helge Larsen/PI-redaktør	Expert opinion " Subcutaneous daratumumab is non-inferior to conventional intravenous daratumumab with lower risk of infusion-related reactions and decreased administration time. Based on these data, and the recent FDA and European Commission approvalsthe widespread use of the subcutaneous formulation for both conventional and investigational practice is supported".
	14/7 08:57 af Helge Larsen/PI-redaktør	Thanks E L. :-)
	14/7 08:54 af E L	full article (link) i suggest reading at least the conclusion and expert opinion
	14/7 08:54 af E L	An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma (link)
	14/7 06:38 af Helge Larsen/PI-redaktør	Foreløbigt er det en nødløsning til vi får råd til en bedre teknisk løsning.
	14/7 06:37 af Helge Larsen/PI-redaktør	Pensionist...Det er i kronogisk orden, men er svært at læse. Det bliver bedre. Det er foreløbigt blot en test. Det er meningen at der kun bliver slået en dag ad gangen op. Det er mere overskueligt.
	14/7 06:34 af Helge Larsen/PI-redaktør	God morgen. :-)
	13/7 22:55 af Helge Larsen/PI-redaktør	Servicemeddelse: Jeg har lavet to chats til Finans- og Økonomikalendere. Jeg opdaterer disse løbende frem over.
	13/7 17:08 af gdn55	Nå, det gik jo ikke så galt idag alligevel.
	13/7 16:20 af E L	another PET/CT Scan trial With the Radioactive Tracer 89Zr-DFO-Daratumumab (link)
	13/7 16:06 af Mcjean	Søg job på Jyllandsposten, din analyse er klart skarpere end deres!
	13/7 14:19 af E L	;)
	13/7 13:53 af Solsen	Thanks I see JW is still CEO ;-)
	13/7 13:34 af E L	(link)
	13/7 11:29 af E L	DnB Markets Rune Majlund Dahl Genmab (Hold, TP: DKK2400.00) - Limited Covid-19 impact We expect slightly lower Darzalex sales in Q2 QOQ due to Covid-19, and estimate global sales of USD936m. We are at the mid-point of the USD3.9bn–4.2bn sales guidance for 2020e.
	13/7 11:25 af GeorgeBest	Nogen estimater på Q2 salgstal torsdag? Jeg lægger ud gæt med USD 980M!
	13/7 10:17 af E L	Lancet - Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial (link)
	13/7 09:10 af Vitus	Det kan nu godt se ud som om der er noget om snakken !!
	13/7 09:09 af Helge Larsen/PI-redaktør	Må dog konstatere at Novo, GEN, ZEAL, BAVA og AMBU falder i åbningen. Så mange kan der da ikke være som læser Jyllandspostens finansside. ;-)
	13/7 09:07 af Helge Larsen/PI-redaktør	Fred være med det. :-)
	13/7 08:53 af Helge Larsen/PI-redaktør	Er det ikke det samme link som jeg lagde i går aftes kl. 20.12. (link)
	13/7 08:00 af Mogan	God morgen :-)